Light therapy using Celeste, Photopharmics’ investigational photo-neuromodulation device, was seen in a clinical trial to ease nonmotor symptoms in people with Parkinson’s disease, and to also improve quality of life for patients. Treatment also showed a trend toward reduced motor symptoms, the study’s main goal, although this effect…
News
The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) status to NouvNeu001, iRegene Therapeutics’ cell therapy for Parkinson’s disease. The FDA based its decision on data from a Phase 1/2 trial (NCT06167681) in China, which showed that the treatment eased motor symptoms in Parkinson’s…
BT-267, an LRRK2 inhibitor being developed by Brenig Therapeutics as a treatment for Parkinson’s disease, has reached sustained, clinically meaningful levels in the brain, according to early results from a study in healthy volunteers. The therapy is being developed for both idiopathic Parkinson’s, where the cause is…
Low muscle mass is more common in people with mild to moderate Parkinson’s disease than in those without the condition, especially in older men, a study found. While it was linked to a slightly larger blood pressure drop shortly after standing, it was not linked to more orthostatic symptoms,…
The American Parkinson Disease Association (APDA) is urging U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to move forward with implementation of the National Parkinson’s Project. The project is an integrated national plan to prevent, diagnose, treat, and ultimately cure Parkinson’s disease.
Herantis Pharma has reported new Phase 1b biomarker data that support the expected mechanism of action of HER-096, its potential disease-modifying treatment for Parkinson’s disease. The Phase 1b trial (NCT06659562) evaluated the safety of HER-096 and explored early signs of biological activity in both healthy volunteers and…
GT-02287, an oral therapy being developed by Gain Therapeutics, was associated with improvements in motor function over three months in people with Parkinson’s disease, including participants both with and without GBA1 mutations. The findings come from an open-label Phase 1b trial (NCT06732180), which also showed lower levels…
Neuralight said a newly completed study showed its machine learning-based system monitoring eye movements via webcam is more sensitive than traditional tests used for tracking Parkinson’s disease progression. “For the first time, a biomarker has outperformed the neurological gold standard in tracking Parkinson’s disease over time, unlocking a new…
Two proteins found on the surface of dopaminergic neurons, the nerve cells that are lost in Parkinson’s disease, may play a crucial role in the spread of toxic alpha-synuclein clumps throughout the brain, and blocking them could slow or halt disease progression. That’s according to a study from Yale…
A new high-tech imaging tool that can “see” the toxic protein clumps thought responsible for Parkinson’s disease is heading into clinical trials to help determine if an experimental therapy can slow the disease. Synusight Biotech has licensed its specialized positron emission tomography (PET) tracer ¹⁸F-FD4 to Abli Therapeutics…
Recent Posts
- Light therapy device seen to brighten life quality for those with Parkinson’s
- When early memories of Parkinson’s came full circle
- FDA grants advanced therapy status to Parkinson’s cell treatment
- Experimental drug BT-267 shows promise in Parkinson’s study
- Saying goodbye to my doctors leaves me sad, but grateful